Efficacy of cognitive enhancers for Alzheimer’s disease: protocol for a systematic review and network meta-analysis

BACKGROUND: Approximately 35 million people world-wide have Alzheimer’s disease and this is projected to nearly double by 2030. Cognitive enhancers, including cholinesterase inhibitors (for example, donepezil, galantamine and rivastigmine) and memantine (N-methyl-D-aspartic acid (NMDA) receptor anta...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Tricco, Andrea C, vanderVaart, Sondra, Soobiah, Charlene, Lillie, Erin, Perrier, Laure, Chen, Maggie H, Hemmelgarn, Brenda, Majumdar, Sumit R, Straus, Sharon E
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2012
Assuntos:
Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3407718/
https://ncbi.nlm.nih.gov/pubmed/22742585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2046-4053-1-31
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados